Decongestion Guided By VExUS Score Or Lung Ultrasound For Renal Recovery In Patients With Cardiorenal Syndrome Type -1

Not Applicable

• Conditions: Cardiorenal Syndrome Type 1
• Interventions: Drug: frusemide

• Registration Number: NCT06786728
• Lead Sponsor: Benha University

Brief Summary

the goal of this observational study is to evaluate the role of VEXUS score and lung ultrasound to guide decongestive therapy in patients with cardiorenal syndrome type -1. the main question it aims to answer is: Can the VEXUS score and lung ultrasound guide the efffect of decongestive therapy on KFR and decongestion metrics in patients with CRS-1 compared to standard assesment ?

Detailed Description

Not available

Study Timeline

• Study Start: 2024-08-10
• Study First Submitted: 2024-12-05
• Status Verified: 2025-01
• Study First Submitted QC: 2025-01-19
• Last Update Submitted: 2025-01-19
• Study First Posted: 2025-01-22
• Last Update Posted: 2025-01-22
• Primary Completion: 2025-07
• Study Completion: 2025-08

Recruitment & Eligibility

• Status: ENROLLING_BY_INVITATION
• Sex: All
• Target Recruitment: 146

Inclusion Criteria

• • Patients of both genders aged 18-65 years old.

  • Patients with CRS1 criteria (worsening of renal function due to acute heart failure manifested by : ( Dyspnea , orthopnea ,hypoxia , congested neck veins , oliguria and congestion in imaging.)
  • Patients with Modified lung ultrasound score(LUSS) more than 15.

Exclusion Criteria

• • Refusal to participate.

  • Patients with renal transplantation.
  • Unknowing baseline creatinine.
  • Patients with a life-threatening indication of RRT (defined as intractable hyperkalemia, acidosis, uremic symptoms) at enrollment,
  • RRT before recruitment,
  • known prehospitalization advanced chronic kidney disease (defined by an estimated GFR <30 mL/min/1.73 m2 or chronic RRT),
  • use of extracorporeal membrane oxygenation (ECMO),
  • diagnosis of hepatic cirrhosis or other condition with portal hypertension
  • Or postrenal causes of AKI

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
the VEXUS group :in this group we use the vexus score to guide decongestive theapy	frusemide	the use of diuretic if vexus score more than 1 at time of enrollement
the lung US group : we use lung ultrasound score to detect degree of pulmonary congestion	frusemide	if lung ultrasound score more than 15 we will start diuretic therapy

Primary Outcome Measures

Name	Time	Method
assesment of KFR using the KDIGO AKI staging improvement	1 week	stage1:serum creatinine increase 1,5 - 2 folds serum creatinine increase 2 - 3 folds serum creatinine increase more than 3 folds

Secondary Outcome Measures

Name	Time	Method
VEXUS score	48 hours	grade 1 : no congestion grade 2:mild congestion grade 3 moderate congestion grade 4 : severe congestion

Trial Locations

Locations (1)

Asmaa Shahat Mohamedy Behairy; 🇪🇬 Cairo, Egypt